Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

This study has been completed.
Janssen Alzheimer Immunotherapy (JAI) Research and Development, LLC
Information provided by (Responsible Party):
Pfizer Identifier:
First received: May 24, 2007
Last updated: February 15, 2013
Last verified: February 2013

To assess the safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization, in patients with mild to moderate Alzheimer's disease.

Condition Intervention Phase
Alzheimer Disease
Biological: ACC-001 + QS-21
Biological: ACC-001
Biological: QS-21
Drug: Placebo: Phosphate buffered saline
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase IIA, Multicenter, Randomized, Third-Party Unblinded, Adjuvant And Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of ACC-001 And QS-21 Adjuvant In Subjects With Mild To Moderate Alzheimer's Disease

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Assess the safety and tolerability of multiple doses of ACC-001 in subjects with mild to moderate AD. [ Time Frame: 2 years participation per patient ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Assess the immunogenicity of each dose level of ACC-001 with or without QS-21 in subjects with mild to moderate AD. [ Time Frame: 18 months ] [ Designated as safety issue: No ]

Enrollment: 86
Study Start Date: May 2007
Study Completion Date: January 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
arm 1: ACC-001 (Vanutide Cridificar)+ QS-21
Biological: ACC-001 + QS-21
Vanutide Cridificar (3, 10, 30µg) + QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
Active Comparator: 2
arm 2: ACC-001
Biological: ACC-001
Vanutide Cridificar (10, 30µg), IM on day 1, month 1, month 3, month 6 and month 12
Placebo Comparator: 3
arm 3: QS-21
Biological: QS-21
QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
Placebo Comparator: 4
Drug: Phosphate Buffered Saline (PBS)
Drug: Placebo: Phosphate buffered saline
Phosphate buffered Saline (pH : 7.4), IM on day 1, month 1, month 3, month 6 and month 12


Ages Eligible for Study:   50 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of probable Alzheimer's Disease with Mini-Mental State Examination (MMSE) score of 16-26 (except Germany: 21-26)
  • Brain MRI consistent with Alzheimer Disease
  • Concurent use of Chloniesterase inhibitor or memantine allowed if stable
  • Other inclusion criteria apply

Exclusion Criteria:

  • Significant Neurological Disease other than Alzheimer's disease
  • Major psychiatric disorder
  • Contraindication to undergo brain MRI
  • Clinically significant systemic illness
  • Other exclusion criteria apply
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00479557

Pfizer Investigational Site
Paris Cedex 13, Paris, France, 75651
Pfizer Investigational Site
Bordeaux, France, 33076
Pfizer Investigational Site
Lille, France, 59037
Pfizer Investigational Site
MARSEILLE cedex 5, France, 13385
Pfizer Investigational Site
Montpellier, France, 34295
Pfizer Investigational Site
Paris, France, 75013
Pfizer Investigational Site
Toulouse, France, 31300
Pfizer Investigational Site
TOULOUSE cedex 9, France, 31059
Pfizer Investigational Site
Berlin, Germany, 14050
Pfizer Investigational Site
Frankenthal, Germany, 67227
Pfizer Investigational Site
Freiburg, Germany, 79106
Pfizer Investigational Site
Goettingen, Germany, 37075
Pfizer Investigational Site
Mannheim, Germany, 68159
Pfizer Investigational Site
Muenchen, Germany, 81675
Pfizer Investigational Site
Muenster, Germany, 48149
Pfizer Investigational Site
Muenster, Germany, 48165
Pfizer Investigational Site
Barcelona, Spain, 08036
Pfizer Investigational Site
Barcelona, Spain, 08025
Pfizer Investigational Site
Barcelona, Spain, 08003
Pfizer Investigational Site
Madrid, Spain, 28040
Sponsors and Collaborators
Janssen Alzheimer Immunotherapy (JAI) Research and Development, LLC
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer Identifier: NCT00479557     History of Changes
Other Study ID Numbers: 3134K1-200, B2571004
Study First Received: May 24, 2007
Last Updated: February 15, 2013
Health Authority: European Union: European Medicines Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Paul-Ehrlich-Institut
Spain: Ministry of Health

Keywords provided by Pfizer:
Alzheimer's Disease
active immunization

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases
QS 21
Adjuvants, Immunologic
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs processed this record on March 01, 2015